Table I.
Baseline characteristics of the entire cohort and serum LDH groups
| Characteristic | Entire cohort (n=1019) |
Normal serum LDH (n=610) |
High serum LDH (n=409) |
P |
|---|---|---|---|---|
|
| ||||
| Age, years; Median (IQR) | 62 (55–69) | 61 (54–68) | 63 (55–70) | 0.02 |
|
| ||||
| Male sex, N (%) | 633 (62%) | 403 (66%) | 230 (56%) | 0.001 |
|
| ||||
| Systolic blood pressure <100mmHg | 226 (22%) | 121 (20%) | 105 (26%) | 0.02 |
|
| ||||
| Organ involved, N (%) | ||||
| >2 organs | 283 (28%) | 151 (25%) | 132 (32%) | 0.008 |
| Cardiac | 744 (73%) | 405 (66%) | 339 (83%) | <0.001 |
| Renal | 645 (63%) | 348 (57%) | 297 (73%) | <0.001 |
| Hepatic | 217 (21%) | 114 (19%) | 103 (25%) | 0.01 |
| Nerve | 194 (19%) | 137 (22%) | 57 (14%) | <0.001 |
| GI | 168 (16%) | 108 (18%) | 60 (15%) | 0.19 |
|
| ||||
| Lambda restricted, N (%) | 755 (74%) | 480 (79%) | 275 (67%) | <0.001 |
|
| ||||
| 2004 Mayo AL amyloidosis stage, % (n=729) | ||||
| I / II / III | 23 / 37 / 40 | 32/ 44 / 24 | 11 / 29 / 60 | <0.001 |
|
| ||||
| 2012 Mayo AL amyloidosis stage, % (n=787) | ||||
| I / II / III / IV | 25 / 24 / 22 / 29 | 30 / 31 / 21 / 18 | 17 / 15 / 25 / 43 | <0.001 |
|
| ||||
| First line treatment, N (%) | ||||
| ASCT | 406 (40%) | 289 (47%) | 118 (29%) | |
| MDex | 272 (27%) | 120 (20%) | 152 (37%) | |
| MP | 104 (10%) | 69 (11%) | 35 (9%) | |
| Bortezomib-based | 59 (6%) | 31 (5%) | 28 (7%) | <0.001 |
| IMiD-based | 45 (4%) | 30 (5%) | 15 (4%) | |
| Dexamethasone alone | 32 (3%) | 20 (3%) | 12 (3%) | |
| No treatment | 71 (7%) | 18 (3%) | 6 (1%) | |
| Unknown | 24 (2%) | 30 (5%) | 41 (10%) | |
| Other | 5 (<1%) | 3 (<1%) | 2 (<1%) | |
Abbreviations: ASCT, Autologous stem cell transplantation, GI, Gastrointestinal; IMiD, Immunomodulatory drug; IQR, interquartile range; LDH, Lactate dehydrogenase; MDex, melphalan-dexamethasone; MP, melphalan-prednisone